TY - JOUR AB - Our previous study demonstrated that PPARĪ³ ligand rosiglitazone prevents gastric carcinogenesis in rats induced by chemical carcinogen N-methyl-N'-nitro-N-nitrosoguanidine (MNNG). In this study, we attempted to identify novel anti-cancer mechanisms of rosiglitazone. By examining the gene expression profiles of MNNG-induced and rosiglitazone-treated gastric cancer with Uniset Rat I Bioarray microarray, we identified a gene that showed prominent responses in the rosiglitazone-treated group. The hypertension-related, calcium-regulated gene (HCaRG) was significantly up-regulated in rat gastric carcinoma of the rosiglitazone-treated group when compared with the MNNG group. We further examined HCaRG expression in human gastric cancer and found that the expression of HCaRG was down-regulated in human gastric cancerous tissue. Rosiglitazone markedly induced the expression of HCaRG in the AGS cell line. The up-regulation of HCaRG may be one of the mechanisms underlying the chemopreventive effect of rosiglitazone in gastric cancer. AD - Department of Gastroenterology, First Affiliated Hospital of Sun Yat-Sen University, Guangzhou, P.R. China null AU - Chen,Bai-Li AU - Yu,Jun AU - Zeng,Zhi-Rong AU - Chu,Wai-Kit AU - Wong,Christine,Y.P. AU - Cheng,Yuen-Yee AU - Sung,Joseph,J.Y. AU - Hu,Pin-Jin AU - Leung,Wai,K. DA - 2008/11/01 DO - 10.3892/or_00000114 EP - 1097 IS - 5 JO - Oncol Rep PY - 2008 SN - 1021-335X 1791-2431 SP - 1093 ST - Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression T2 - Oncology Reports TI - Rosiglitazone suppresses gastric carcinogenesis by up-regulating HCaRG expression UR - https://doi.org/10.3892/or_00000114 VL - 20 ER -